Tryton Medical Announces Events at EuroPCR 2013 in Paris

Durham, N.C. – May 13, 2013 – Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, today announced activities highlighting the latest data and experience with the Tryton Side Branch Stent at EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions, taking place at the Palais des Congrès May 21-24, 2013 in Paris. The company will exhibit in booth M27 (Level 2).

- On Wednesday, May 22 the following lectures will discuss the Tryton Side Branch Stent:
  
  o During the session "Left Main Treatment: Dedicated Stents, Complex Strategies and Post-CABG Situation", Eulogio J. Garcia, M.D. will present a case study examining a double bifurcation lesion treated with two dedicated side branch stents and a single drug-eluting stent (DES). The presentation will take place between 8:00-9:30 a.m. in the Abstract & Case Corner Forum.

  o During the session "Use of OCT during PCI", Joanna Wykrzykowska, M.D. will present on "Successful treatment of a complex bifurcation lesion with extensive side branch involvement with bioresorbable vascular scaffolds in combination with a dedicated bifurcation side branch stent: evaluation and new insights with 3D-OCT". The presentation will take place between 3:40-4:40 p.m. in Room 351.

- On Thursday, May 23, Maik Grundeken, M.D. will present an oral abstract examining the clinical outcomes from 759 patients treated with the Tryton Side Branch Stent after final kissing balloon inflation compared with no final kissing balloon inflation in bifurcation lesions. The presentation will take place at 8:33 a.m. in Room 243. This data set is a sub analysis of data from 905 patients treated with the Tryton Side Branch Stent in 8 European post-marketing registries. The 905 patient data set demonstrated low target lesion revascularization rates of 2.9 percent at six months and 4.0 percent at one year, and a low 0.5 percent thrombosis rate at one year.

- On Thursday, May 23, Martin B. Leon, M.D. and Patrick W. Serruys, M.D. will chair a symposium regarding the Tryton Side Branch Stent. The symposium will examine the growing body of clinical evidence, the real-world experience with the device, and the emerging evidence base regarding its use to address left main coronary artery disease.
Antonio Bartorelli, M.D., Joanna Wykrzykowska, M.D., Jens F. Lassen, M.D., Robert-Jan van Geuns, M.D., and Yaron Almagor, M.D. are scheduled to present at the symposium. The symposium will take place from 4:45-6:15 p.m. in Room 241 (Level 2).

Tryton has completed enrollment in the first and only randomized controlled U.S. IDE pivotal clinical trial evaluating a dedicated bifurcation stent. The company anticipates study outcomes will be presented at TCT 2013 in San Francisco.

About Coronary Bifurcation Disease
Coronary artery disease often results in the buildup of plaque at the site of a bifurcation, where one artery branches from another. Current approaches to treating these lesions are time consuming and technically difficult. As a result, the side branch is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of the stented vessel following implantation. In patients undergoing PCI-stenting, approximately one-third have a bifurcation lesion. Left main disease, an accumulation of plaque that narrows the base of the coronary tree, is a persistent challenge in interventional cardiology, as more than 75 percent of left main lesions are bifurcation lesions.

About the Tryton Side Branch Stent System
The Tryton Side Branch Stent System is built for bifurcation using proprietary Tri-ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single-wire balloon-expandable stent delivery system. A conventional drug-eluting stent is then placed in the main vessel.

About Tryton Medical, Inc.
Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D. (professor of medicine at Dartmouth Medical School/Dartmouth-Hitchcock Medical Center) and Dan Cole of Spray Venture Partners to develop stents for the definitive treatment of bifurcation lesions. Privately held, Tryton is backed by PTV Sciences, RiverVest Venture Partners, Spray Venture Partners, and the 3x5 Special Opportunity Fund. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

# # #